Related Experiment Videos
Developments in the treatment of chronic hepatitis C
1Division of Gastroenterology/HepatologyThe Scripps Clinic, 10666 N. Torrey Pines Road, La Jolla, CA 92037, USA. ppockros@scrippsclinic.com
Insights
Hepatitis C virus (HCV) affects 170 million globally, with current treatments like interferon showing limited efficacy. New antiviral agents are crucial for managing difficult-to-treat cases and improving patient outcomes.
Area of Science:
- Hepatology
- Virology
- Infectious Diseases
Background:
- Hepatitis C virus (HCV) is a major global health concern, causing chronic liver disease in 50-85% of infected individuals.
- Current treatments, primarily interferon-alpha (IFN-alpha) with ribavirin, face challenges including limited efficacy, toxicity, and patient adherence.
Purpose of the Study:
- To review the current landscape of Hepatitis C virus (HCV) treatment.
- To highlight the limitations of existing therapies and the urgent need for novel antiviral agents.
- To explore emerging therapeutic strategies for HCV infection.
Main Methods:
- Review of existing literature on HCV epidemiology, pathogenesis, and treatment.
- Analysis of the efficacy and limitations of current IFN-alpha-based therapies.
- Investigation into novel therapeutic approaches targeting HCV replication and host response.
Main Results:
- HCV affects 170 million worldwide, with chronic infection developing in a significant majority.
- Standard interferon therapy, even with ribavirin, demonstrates suboptimal efficacy, particularly in difficult-to-treat populations (e.g., cirrhosis, genotype 1).
- Significant challenges remain, including treatment toxicity, cost, and patient adherence.
Conclusions:
- The development of new Hepatitis C virus (HCV) antiviral agents is critical for effective disease management.
- Promising strategies include long-acting interferons, immunomodulators, antifibrotics, and direct-acting antivirals targeting viral enzymes and replication processes.
- Further research into novel molecular approaches like ribozymes and antisense oligonucleotides is essential.
Abstract:
Hepatitis C virus is the most common chronic, blood-bourne infection, affecting 170 million people worldwide, approximately 3% of the global population. Of those infected with hepatitis C virus, 50 - 85% will develop chronic hepatitis C. Although hepatitis C is primarily a disease of the liver, a diagnosis is currently defined by the presence of the hepatitis C virus and treatment success is defined by the clearance of the virus. IFN-alpha is currently the mainstay of chronic hepatitis C therapy; the antiviral and anti-inflammatory components of IFN target both the infectious and the hepatic manifestations of the disease. However, even in combination with ribavirin, interferon therapy is not fully efficacious. Recently, the search for a more effective treatment has led investigators to optimise interferon therapy by developing pegylated interferons. Challenges facing our current treatment of hepatitis C virus include lack of efficacy in patients with difficult-to-treat disease, such as patients with cirrhosis or infected with hepatitis C virus genotype 1 (who represent a majority of US hepatitis C virus infections), the toxicity of combination therapy, the expense and difficulty of therapy and the poor reception of these treatments by many patients. The development of new hepatitis C antiviral agents is critical to our management of this disease. A number of approaches are under investigation, including long-acting interferons, immunomodulators, antifibrotics, specific hepatitis C virus-derived enzyme inhibitors, drugs that either block hepatitis C virus antigen production from RNA or prevent normal processing of hepatitis C virus proteins and other molecular approaches to treating hepatitis C virus, such as ribozymes and antisense oligonucleotides.